Supply Chain Archives
05/29/2025
Starting Smart: How to Structure an Integrated Supply Chain in Early-Stage CGT Programs
For many academic labs, technology spinouts, and early-stage CGT companies, the temperature-controlled supply chain feels like something to figure out later. But when dealing with highly sensitive starting materials and therapies like CGTs, later can quickly become too late. Whether you’re preparing for first-in-human trials or just beginning to plan for scale, integrated thinking now can spare you time, cost, and complexity later.
05/19/2025
Clinical Trials Day: Supporting the Journey from Discovery to Delivery
Clinical trials represent hope, innovation, and the pursuit of better outcomes. They are the backbone of developing new diagnostics, vaccines, devices, and therapies. They help ensure safety, efficacy, and accessibility to the people who need them. That's why each year on May 20, the community comes together to celebrate Clinical Trials Day, honoring the anniversary of the first randomized clinical trial. At Cryoport Systems, we are honored to support our partners and clients in this journey.
01/30/2025
Mapping the Future: Q&A with Mark Sawicki, Ph.D., on 2025 Trends in Cell and Gene Therapy
As the CGT industry enters a pivotal phase of commercial growth and therapy expansion, Cryoport Systems’ CEO, Mark Sawicki, Ph.D., shares his perspectives on where the market is headed.
01/13/2025
Top 10 Industry Predictions for 2025
Cryoport Systems’ CEO, Mark Sawicki, provides a comprehensive analysis into the challenges and growth opportunities shaping the CGT industry.
12/16/2024
Solving Key Gene Therapy Logistics Challenges with Advanced Technology
Cryoport Systems developed the Cryoport Elite™ Ultra Cold shipping system with one mission in mind: to ensure that gene therapies reach their destination intact, uncompromised, and ready for patient treatment.
02/22/2024
Examining 2023 & 2024: What’s to Come with President & CEO, Mark Sawicki
The cell and gene therapy industry is poised for many changes in 2024. With persistent challenges facing manufacturers and developers such as the retention of experienced talent or a general lack of funding for specialized therapies, the state of what’s to come feels more unsure than it has in recent years.
12/21/2023
